CHIMERIX INC (CMRX)
US16934W1062 - Common Stock
Overall CMRX gets a fundamental rating of 3 out of 10. We evaluated CMRX against 588 industry peers in the Biotechnology industry. While CMRX has a great health rating, there are worries on its profitability. CMRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CMRX had negative earnings in the past year.
In the past year CMRX has reported a negative cash flow from operations.
In the past 5 years CMRX reported 4 times negative net income.
CMRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CMRX's Return On Assets of -38.59% is fine compared to the rest of the industry. CMRX outperforms 61.82% of its industry peers.
CMRX has a Return On Equity of -42.53%. This is in the better half of the industry: CMRX outperforms 73.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.59% | ||
| ROE | -42.53% | ||
| ROIC | N/A |
ROA(3y)-49.77%
ROA(5y)-59%
ROE(3y)-76.39%
ROE(5y)-78.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CMRX has a Gross Margin of 100.00%. This is amongst the best in the industry. CMRX outperforms 99.66% of its industry peers.
The Profit Margin and Operating Margin are not available for CMRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CMRX has more shares outstanding
The number of shares outstanding for CMRX has been increased compared to 5 years ago.
There is no outstanding debt for CMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CMRX has an Altman-Z score of -3.26. This is a bad value and indicates that CMRX is not financially healthy and even has some risk of bankruptcy.
CMRX has a Altman-Z score (-3.26) which is comparable to the rest of the industry.
CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.26 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 10.25 indicates that CMRX has no problem at all paying its short term obligations.
The Current ratio of CMRX (10.25) is better than 80.65% of its industry peers.
CMRX has a Quick Ratio of 10.25. This indicates that CMRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.25, CMRX belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.25 | ||
| Quick Ratio | 10.25 |
3. Growth
3.1 Past
The earnings per share for CMRX have decreased strongly by -146.94% in the last year.
CMRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.04%.
Measured over the past years, CMRX shows a very negative growth in Revenue. The Revenue has been decreasing by -46.25% on average per year.
EPS 1Y (TTM)-146.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q16.67%
Revenue 1Y (TTM)-99.04%
Revenue growth 3Y-60.78%
Revenue growth 5Y-46.25%
Revenue growth Q2Q-99.51%
3.2 Future
The Earnings Per Share is expected to grow by 13.52% on average over the next years. This is quite good.
Based on estimates for the next years, CMRX will show a very strong growth in Revenue. The Revenue will grow by 249.31% on average per year.
EPS Next Y5.76%
EPS Next 2Y-2.95%
EPS Next 3Y7.34%
EPS Next 5Y13.52%
Revenue Next Year1301.81%
Revenue Next 2Y141.14%
Revenue Next 3Y341.61%
Revenue Next 5Y249.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CMRX. In the last year negative earnings were reported.
Also next year CMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.95%
EPS Next 3Y7.34%
5. Dividend
5.1 Amount
CMRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHIMERIX INC
NASDAQ:CMRX (4/25/2024, 10:21:58 AM)
0.905
-0.01 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap80.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.59% | ||
| ROE | -42.53% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.25 | ||
| Quick Ratio | 10.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-146.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-99.04%
Revenue growth 3Y-60.78%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y